NICE rejects Perjeta for Breast Cancer
The National Institute for Health and Care Excellence (NICE) will not in new draft guidance recommend Perjeta (pertuzumab) from Roche for use in combination with Herceptin and docetaxel, for HER2-positive Breast Cancer tumours which have either recurred in the breast or spread to other parts of the body.
NICE is not convinced that Perteta represents value for money. The drug is not recommended because clinical data presented to the independent appraisal committee at NICE could not predict how long the drug might extend lives, yet it appears to cost much more than current NHS treatments.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.